Targeted Therapy Technologies, LLC

Central Admixture Pharmacy Services (CAPS) is the largest network of outsourcing admixture pharmacies in the United States, offering high-quality compounding services and solutions to hospitals and outpatient facilities nationwide. With over 30 years of experience, CAPS provides customized, patient-specific compounding needs through their 22 regional pharmacies and distributes non-patient-specific compounded sterile preparations through their FDA-registered outsourcing facilities. As a pioneer in the outsourcing of compounded sterile preparations, CAPS is committed to delivering confidence and ensuring patient safety by eliminating dual order entry and decreasing transcription errors. Their comprehensive compliance program, in accordance with the Compliance Program Guidance for Pharmaceutical Manufacturers, ensures the highest quality standards are met. CAPS also offers consulting, training, and educational services to further support their customers' needs.Generated from the website

Urovant Sciences, Inc, based in Irvine, CA, is a global healthcare company dedicated to improving the health and well-being of people worldwide. With a focus on critical areas such as psychiatry, neurology, oncology, urology, women's health, rare disease, and cell gene therapy, Urovant drives innovation in treatments, science, and technology to address patient needs. As a subsidiary of Sumitomo Pharma Co., Ltd, Urovant Sciences embodies the promise of combining technology and life-sciences expertise to deliver measurable improvements in patient outcomes. With a diverse pipeline of preclinical and clinical programs, Urovant is committed to fueling breakthroughs and providing patient-first solutions through a technology-driven approach.Generated from the website

Stason Pharmaceuticals is a US-based pharmaceutical company headquartered in Irvine, California, specializing in the development of partnerships and drugs within oncology, renal, and orphan indications. With its contract service divisions, MPhS and Western PharmSci, the company provides comprehensive contract packaging, analytical testing, and CDMO services to drug-development companies, supporting both clinical trial materials and commercial production of high-potency products. Since entering the US generic market in 1994, Stason has established a diverse portfolio and a global network of distributors. The company combines its advanced manufacturing capabilities, including high containment facilities, with strategic alliances across the US, Canada, Europe, and Asia to foster innovation and ensure compliance with industry standards. Generated from the website